Hannah Deresiewicz is an Executive Vice President and Managing Director at Stern IR, based in New York City. Since joining the firm in 2013, Hannah has had the privilege of working with companies of all shapes and sizes, across a wide variety of therapeutic areas including oncology, cardiovascular disease, renal/metabolic disease and rare conditions. She has advised companies through an array of financing and strategic processes – crossover rounds, IPOs and follow-ons, as well as reverse mergers and multi-billion dollar acquisitions – and has shaped and implemented communications around clinical trial data, product approvals and launches, large-scale collaborations and corporate respositionings. Hannah’s favorite part of her job is getting to work closely and collaboratively with her clients, and she feels extremely lucky to learn from, and partner with, such a diverse group of industry professionals.
Hannah graduated from Columbia University summa cum laude with a degree in Political Science and Sociology.
